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Abstract
P53 protein is more frequently mutated in human tumours compared with the other proteins.
While the majority of the p53 mutations, especially within its DNA-binding domain, lead to
the loss of the wild-type function, there are accumulating data demonstrating that the p53
mutants gain tumour promoting activities; the latter triggers a revitalised interest in functional
analysis of the p53 mutants. A systematic screening for p53 mutations in surgical materials
from patients with glioma revealed a 378C>G mutation that creates a stop codon at the posi-
tion of amino acid residue 126. The mutation eliminates the recognition site for the restriction
endonuclease Sca I that allowed us to carry out RFLP analysis of DNA extracted from the
clinical samples and suggests that this mutation is more frequent than is documented in the
p53 databases. Both the ECV-304 and EJ cell lines, that probably originate from the bladder
carcinoma T24 cell line, were confirmed to contain the homozygous 378C>G mutation but
were shown to produce the p53 protein of expected full-length size detected by Western
blotting. We provide evidence that the 378C>G mutation generates an alternative 3’ splice
site (ss) which is more often used instead of the authentic upstream 3’ ss, driving the produc-
tion of mRNA encoding the protein with the single amino acid deletion (p53ΔY126). Using
endogenous expression, we demonstrated that the p53ΔY126 protein is nearly as active as
the wild type protein in inducing the p21/Waf1 expression and apoptosis.
Introduction
The p53 protein is a major player of numerous pathways that regulate cellular responses to
stress. The p53 gene is the most commonly mutated gene in human cancers [1–3]. The p53
protein is considered to be a tumour suppressor because it blocks tumour development by trig-
gering apoptosis or cellular senescence in response to oncogenic stress. Mutant p53 proteins
are highly expressed in a variety of different cancer cells, and the majority of p53 mutations are
missense mutations found in the DNA binding domain encompassing exons 5–8 of the gene







Citation: Makarov EM, Shtam TA, Kovalev RA,
Pantina RA, Varfolomeeva EY, Filatov MV (2017)
The rare nonsense mutation in p53 triggers
alternative splicing to produce a protein capable of
inducing apoptosis. PLoS ONE 12(9): e0185126.
https://doi.org/10.1371/journal.pone.0185126
Editor: Sumitra Deb, Virginia Commonwealth
University, UNITED STATES
Received: May 31, 2017
Accepted: September 5, 2017
Published: September 29, 2017
Copyright: © 2017 Makarov et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
[4,5]. Overall, p53 mutations are conventionally divided into two groups: those that alter the
amino acid residues responsible for forming sequence-specific contacts with DNA, and those
that change the p53 protein conformation which, in turn, affects the protein stability or dis-
rupts interactions with its protein partners [6]. For many years, loss of p53 function through
mutations, especially in the DNA binding domain which disrupts transcriptional regulation of
target genes, was considered as the predominant contribution of p53 into oncogenesis [1].
This led to the hypothesis that restoration of wild-type p53 expression in tumour cells may
eliminate malignant formations [7]. The idea was proven in a number of mouse model studies
where it was shown that restoring the wild-type p53 activity, using different methodologies,
led to tumour regression [8–10]. Another approach is a pharmacological reactivation of the
mutant p53 which was successfully developed to restore the functionality of some of the p53
mutants using the small molecules, e.g., PRIMA-1 [11] and PK7088 [12]; the former is cur-
rently tested in the clinical trials [13].
New therapeutic strategies are likely to be developed in the future in view of emerging
appreciation of novel oncogenic functions of the mutant p53 proteins. Instead of being focused
solely on loss of wild-type functions in mutant p53, the research turned towards investigating
a gain of tumour-promoting functions of mutant p53 [14,15]. Recently, gain-of-functions,
including increased invasion, migration, and angiogenesis, were reported in a number of cell
lines with different p53 mutations. Moreover, mouse models carrying the specific mutations of
p53 often develop a wider repertoire of more aggressive tumours [15,16]. Several models
explaining the mechanism of cellular action of the different p53 mutants were proposed and
partially proven [16]. Most of these models rely on the ability of mutant p53 proteins to estab-
lish a new network of protein-protein interactions, or trigger conformational changes affecting
either the p53-dependent transcriptional machinery or activating/downregulating expression
of non-p53 target genes. However, more investigations are required to understand the molecu-
lar function of particular p53 mutants in certain cellular contexts.
Numerous cell lines with a variety of p53 mutations, originated from cancer patients, are in
constant use in a great number of laboratories around the world; however, p53 mutational sta-
tus and its effect on the cellular phenotype is still a controversial issue for many of the cell lines
[17–19]. This can lead to erroneous interpretations of experimental results; therefore, a careful
re-examination of p53 status of widely used cell lines is an important task.
This study investigates a rare C>G nucleotide substitution at position 378 of the p53 protein
that creates a stop codon at the position of amino acid residue 126, and provides evidence that,
in this mutant, premature termination of translation is avoided via a mechanism of alternative
pre-mRNA splicing, generating the protein with the single amino acid deletion (p53ΔY126)
that exhibits at least some functions of the wild-type protein.
Materials and methods
Cell lines and clinical samples
The HeLa human cervical carcinoma, K562 human chronic myeloid leukemia and ECV-304
transformed human endothelial cell lines were obtained from the Cell Culture Collection of
the Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia. The NB1-T
human fibroblast cell line, generated from normal NB1 fibroblasts [20] by transfection with
the hTERT cDNA [21] and EJ human bladder carcinoma cell line were from the Biosciences
Cell Collection of Brunel University London, UK. The GL-V cell line was generated in our lab-
oratory from surgical material of a patient with glioma provided by Polenov Institute of Neu-
rosurgery, St. Petersburg, Russia. K562 cells were grown at 37˚C with 5% CO2 in RPMI media
and the other cell lines were cultured in DMEM; all supplemented with 10% foetal bovine
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serum and 1% penicillin-streptomycin. Formalin-fixed paraffin-embedded (FFPE) tumour
tissue samples were received from Archives of Petrov Institute of Oncology, St Petersburg.
The set of blood samples from cancer patients used in the RFLP analysis was obtained from
Regional Hospital, Gatchina, Russia. Part of the research, including human materials acquired
with informed consent, was approved by the Ethics Committee of Polenov Institute of Neuro-
surgery, St. Petersburg. The Institute is authorised to perform research involving human par-
ticipants according to guidelines from the Ministry of Healthcare of the Russian Federation
that are in agreement with the principles expressed in the Declaration of Helsinki.
Plasmid constructions and cell transfections
The open reading frame (ORF) with 60 nucleotides of the 50 untranslated region of the human
wild type p53 gene, the first 125 amino acids (p53-aa125) and p53ΔY126 (amplified from the
EJ cDNA), were cloned upstream and in-frame with EGFP into the vector pEGFP-N1. Trans-
fections were performed 24 hours after seeding 5×104 cells per well in 6-well tissue culture
plates with 1 μg of the appropriate plasmids using Effectene Transfection Reagent (Qiagen) or
X-tremeGENE HP DNA Transfection Reagent (Roche) according to manufacturer’s instruc-
tions. 48 hours after transfection, the cells were either examined for apoptosis by flow cytome-
try or collected for western blotting analysis. Attempts to generate stable cells were carried out
by maintaining the transfected cells in media containing 400 μg/mL of antibiotic G418.
Sub-cellular localisation of the p53-EGFP protein
NB1-T cells growing on glass coverslips in 6-well tissue culture plates were transfected with
the aforementioned plasmids. 24 hours after transfection cells were fixed with 4% parafor-
maldehyde, counterstained with DAPI (5 μg/mL), and analysed by confocal fluorescent
microscopy.
RFLP analysis
DNA was extracted from cultured cells, FFPE and blood samples using PureLink Genomic
DNA kit (ThermoFisher Sientific) according to the manufacturer’s instructions or by the rou-
tine Proteinase K-Phenol/Chloroform extraction method. DNA was quantified using a Nano-
Drop spectrophotometer and subjected to PCR amplification using using Phusion Hot Start
DNA polymerase (ThermoFisher Scientific). The 453 base-pairs fragment from intron 4 to
exon 6 of the p53 gene was produced using the In4.F forward primer—GCTGCCGTCTTCC
AGTTGC and the Ex6.R reverse primer—CTCAGGCGGCTCATAGGGC, and then subjected to
restriction enzyme digestion with Sca I followed by agarose gel analysis.
The p53 cDNA analysis
Total RNA was extracted from ECV-304 and EJ cells using NucleoSpin RNA II kit (Macherey-
Nagel) and converted into cDNA using random hexamer primers and Superscript III reverse
transcriptase (Invitrogen); both procedures were carried out according to the manufacturer’s
protocols. Alternatively, the cDNA was generated by reverse transcription using oligo(dT)
primers. The 447 base-pair fragment of p53 ORF encompassing exon 4 to exon 6 was amplified
using Phusion Hot Start DNA polymerase and the Ex4.F forward primer—GCACCAGCAGC
TCCTACACC and the Ex6.R reverse primer. The PCR product was cloned into pJET2.1 vector
and a number of clones were sequenced by GENEWIZ UK Ltd.
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Western blotting
For protein analysis of p53 and p21/Waf1 expression, whole cell extracts were prepared from
1–5 x106 cells lysed in 30–50 μL of buffer containing 10 Tris-HCl pH 7.4, 0.1% Triton X-100,
5 PMSF, 5 MgCl2, 5 u/mL DNAse I, 20 β-mercaptoethanol, followed by sonication. 20 μg of
total protein, as estimated by Bradford assay (Pierce), were resolved by 10% SDS–PAGE and
transferred to a PVDF membrane. These were hybridised with either mouse monoclonal p53
antibody (clone DO-1, Sigma) at a 1:1,000 dilution, or p21/Waf1 (clone CP74, Millipore) at a
1:1,000 dilution followed by treatment with the peroxidase-labeled anti-mouse IgG (whole
molecule) antibody (Sigma) at a 1:10,000 dilution. GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) was utilised as an endogenous control for equal loading using the monoclonal
antibody ZG003 (ThermoFisher Scientific) at a 1:10,000 dilution. Antibody binding was
detected by enhanced chemoluminescence (Pierce). Precision Plus Protein Dual Color stan-
dards (Bio-Rad) were used to estimate the molecular weight of the detected proteins.
Cell viability assay
The assay was carried out according to Franken et al., 2006 [22]. Briefly, 5×103 GL-V cells
were seeded per well into 24-well tissue culture plates and were transfected after 24 hours with
0.4 μg of the corresponding plasmids using Effectene Transfection Reagent (Qiagen). The next
day, G418 (Geneticin) was added to the medium to a final concentration of 400 μg/mL to select
cells that had acquired neomycin resistance from the plasmid. These were cultivated for 2
weeks in the presence of antibiotic. Cells were fixed with glutaraldehyde and stained using
crystal violet (0.1% in 20% methanol).
Flow cytometry
The flow cytometric analysis of propidium iodide stained cells was employed to assess cell apo-
ptosis as described by Belloc et al., 1994 [23]. Briefly, 48 hour after transfection, 1 mL of the
K562 cell suspension containing 105 cells was incubated with 100 μL of propidium iodide
(50 μg/mL) for 4 minutes, and were analysed on a Beckman Coulter Cell Lab Quanta SC Flow
Cytometer. The cells emitting green fluorescence (generated from the plasmid) were taken
into consideration and compared with the number of cells emitting red fluorescence due to
propidium iodide staining. Results of three individual transfections with each of the plasmids
were used to calculate the percentage of apoptotic cells.
Results
Mutation analysis of p53 via exon sequencing is commonly used in clinical practice for assess-
ment of p53 functionality in surgically removed tumours. Through a joint programme with
Polenov Institute of Neurosurgery, St Petersburg, Russia, we identified a C to G nucleotide
substitution at position 378 of the p53 open reading (378C>G mutation) in one DNA sample
extracted from surgical material of a patient with glioma. This mutation is considered to be
rare according to IARC (International Agency for Research on Cancer, R18, April 2016 is the
latest) p53 database and has not been reported previously in gliomas [4]. We realised that the
378C>G mutation eliminates the recognition site (AGT/ACT) for the Sca I restriction endo-
nuclease allowing a simple RFLP (Restriction Fragment Length Polymorphism) analysis of
genomic DNA using the Sca I restriction enzyme digestion. We employed this analysis to the
samples available to us from Petrov Institute of Oncology, St Petersburg, and Regional Hospi-
tal, Gatchina, Russia. This included DNA extracted from 11 formalin-fixed, paraffin-embed-
ded (FFPE) tissue sections of colorectal cancer, 13 FFPE of gastric cancer, and 18 samples of
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DNA extracted from lymphocytes of patients with the different types of cancer. Fig 1 shows an
example of RFLP analysis. We have found one DNA sample (#36 in Fig 1) originated from
FFPE tissue sections of colorectal cancer that contains the same 378C>G mutation (also veri-
fied by sequencing) out of 42 tumor samples available to us. This indicates that this mutation
may occur more frequently in cancer patients compared to the p53 database where it was
reported in seven different cell lines [4]. The Sca I restriction digestion analysis could be easily
employed to accumulate statistical data on frequency of this mutation.
To investigate the effect of the 378C>G mutation at the cellular level, we performed in silico
analysis of the p53 and the cell line databases and found three cell lines containing the same
mutation: ECV-304—initially described as a spontaneously transformed cell line derived from
a Japanese human umbilical vein endothelial cell culture; EJ and T24 –both are urinary bladder
carcinoma. These cell lines are subject to controversy as they are suspected of being cross-con-
taminated, and are currently believed to be originating (if not identical) from the T24 cell line
(see Discussion). However, since both ECV-304 and EJ cells were available to us, we decided
Fig 1. RFLP analysis of genomic DNA to detect the 378C>G mutation in the p53 gene. DNA, extracted
from the four formalin-fixed paraffin-embedded tissue samples of colorectal cancer, was amplified using the
primers annealing to intron 4 (forward) and exon 6 (reverse) and the PCR products were subjected to the Sca
I restriction enzyme digestion. (A) Schematic presentation of amplified and the Sca I digested fragments on
the p53 gene. Numbers indicate the sizes of DNA fragments in base pairs (bp). The band of 453 bp after the
restriction enzyme digestion indicates the absence of Sca I site which is a characteristic of the 378C>G
mutation. The band of 380 bp is a product of the Sca I restriction enzyme digestion and is synonymous to the
wild type p53 gene. (B) Agarose gel electrophoresis of the amplified DNA fragments before (-) and after (+)
the restriction enzyme digestion. Molecular weight markers from HyperLadder II (Bioline) are shown in bp on
the right.
https://doi.org/10.1371/journal.pone.0185126.g001
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to investigate the p53 status in these cell lines. Moreover, there were contradictory data on p53
mutations in EJ cells varying from no mutations [24] to point mutations at the different nucle-
otides [25,26]. We carried out sequencing analysis of genomic DNA and cDNA and confirmed
the presence of the 378C>G mutation in both ECV-304 and EJ cells from our collections. We
have also revealed that both ECV-304 and EJ cells are homozygous in respect to the 378C>G
mutation as no Sca I digestion was detected by RFLP analysis of their genomic DNA. No muta-
tion at position 490A>G (K164E), reported by Rieger et al., 1995 [25], was detected either in
ECV-304 or EJ cell line, and we did not find any other mutations in addition to the 378C>G
mutation in the p53 cDNA from our cell lines.
A C>G nucleotide substitution at position 378 of the p53 open reading frame creates the
stop codon (TAG) instead of tyrosine at amino acid position 126 (Y126 –TAC). Since this is a
homozygous mutation, all the mRNAs encoding the p53 protein should contain the stop
codon which could trigger nonsense mediated decay (NMD) of the p53 mRNA or, at best, lead
to production of truncated protein of 125 amino acids exclusively. However, Western blotting
analysis revealed the presence of p53 protein of expected full-length size in both ECV-304 and
EJ cells (Fig 2A). Moreover, this is the only protein detected by the DO-1 monoclonal p53 anti-
body that recognises the N-terminal epitope mapped between amino acid residues 11–25 of
human p53 protein (Fig 2B). As a negative control, the GL-V cell line generated in our labora-
tory (St Petersburg, Russia) from the surgical material of the patient with glioma, was used
because it contains an extended deletion of the p53 gene encompassing almost the entire open
reading frame (S1 File, Supporting Information). p53 dependent cell cycle arrest mediates the
transactivation of the p21/Waf1 gene, which encodes the inhibitor of cyclin-dependent kinases
[27]. Sodium butyrate (NaBu), a histone deacetylase inhibitor, induces p21/Waf1 expression
[28], hence we investigated the effect of NaBu on ECV-304 and EJ cells. Indeed, p21/Waf1 pro-
tein level was increased in response to NaBu treatment in both ECV-304 and EJ cells, whereas
no the p21/Waf1 induction was observed in GL-V cells where the p53 gene is deleted (Fig 2C).
It is evident that a discrepancy exists as all of the mRNAs encoding the p53 protein in ECV-
304 and EJ cells can only drive the production of truncated protein of 125 amino acids, yet
the presence of a full-length protein with the Western blotting is observed. Moreover, this p53
protein is functionally active if it is involved in the NaBu-dependent induction of p21/Waf1
expression. One possibility that may account for this occurrence is a stop codon readthrough.
However, the premature termination codons (PTC) are readthrough by the ribosomes with
such a low frequency that this phenomenon can hardly explain the amount of p53 detected on
the blots (see Discussion). The other possibility is that the 378C>G mutation generates an
Fig 2. Analysis of p53 expression in ECV-304 and EJ cells. (A) Western blotting analysis of p53 protein in HeLa, GL-V, ECV-304 and EJ cells. (B) The full-
length Western blot of EJ and GL-V cells probed with the p53 antibody. The molecular weight protein markers are indicated on the right. (C) Immunodetection
of p21/Waf1 protein in ECV-304, EJ and GL-V cells before (-) and after exposure to 10 mM of sodium butyrate (NaBu) for 24 h (+). Immunodetection of
GAPDH protein is used as an endogenous control.
https://doi.org/10.1371/journal.pone.0185126.g002
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alternative 3’ splice site (ss) which, if efficiently used instead of the authentic upstream 3’ ss,
would lead to the production of mRNA encoding the protein with single amino acid deletion
(Y126) (Fig 3A). The p53ΔY126 protein is unlikely to be distinguished from a full-length pro-
tein by their migration on SDS-PAGE, hence the signal on the Western blots of ECV-304 and
EJ proteins (Fig 2A) is the p53ΔY126 protein. To investigate this hypothesis, we amplified the
DNA fragments from exon 4 to the end of the exon 6 from cDNA generated from total RNA
extracted from ECV-304 and EJ cells, and sequenced the PCR product. Fig 3B shows the
mixed sequence starting after the first nucleotide of exon 5 (position 376 in p53 ORF) which
would correspond to the two splice isoforms: ACG/TAGTCC and ACG/TCC, the latter repre-
sents the deletion of the mutated Y126 (TAG>TAC). To confirm the sequencing and estimate
the frequency of the alternative splicing event, we cloned the PCR product into pJET2.1 vector,
Fig 3. Sequence analysis of the 378C>G mutation in p53 protein. (A) Schematic representation of the Exon
4-intron-Exon 5 boundaries demonstrating how the G for C substitution creates an alternative 3’splice site which, if
used, eliminates the stop codon from the mutated mRNA. The three proteins are designated here as p53-WT,
p53-aa125, p53ΔY126. (B) Sequence analysis of exon 4-exon 5 junction in the PCR product amplified from cDNA
of EJ cells. (C, D) The representative chromatograms of the sequenced clones corresponding to p53-aa125 and
p53ΔY126, respectively. The nucleotides of exon 4 are highlighted in blue. The chromatogram was generated
using FinchTV software.
https://doi.org/10.1371/journal.pone.0185126.g003
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and sequenced a number of clones. Analysis revealed that 10 out of 20 sequenced clones from
the ECV-304 cDNA and 10 out 14 sequenced clones from the EJ cDNA contain the deletion of
three nucleotides encoding Y126 (Fig 3D). The rest of the clones contain TAG instead of Y126
corroborating the genomic sequencing (Fig 3C). Thus, the nonsense mutation at the beginning
of exon 5 indeed activates the alternative 3’ss, allowing the stop codon to be skipped and p53
protein being synthesised with the single amino acid deletion in more than 50% of splicing
events. The presence of mRNAs containing the stop codon contradicts to the fact these RNAs
meet the requirements for nonsense-mediated decay (NMD) and are supposed to be degraded.
Moreover, the truncated protein of 125 amino acids was not detected by Western blotting (Fig
2B). To reveal whether the RNAs contain the poly(A) tail or not, we carried out reverse tran-
scription of total RNA from EJ cells using oligo(dT); amplified the fragment encompassing
mutation; cloned the PCR products and sequenced. We found that 3 out of 13 sequenced
clones contain the stop codon that is similar (4 out of 14) to the EJ cDNA generated using ran-
dom hexamers. The result indicates that a number of mRNAs containing the stop codon may
escape NMD, and therefore, the truncated protein of 125 amino acids (p53-aa125) can be
potentially synthesised.
Next, we investigate whether the p53ΔY126 protein has functional properties similar to the
wild type protein or not. Since the mRNAs encoding the p53-aa125 were detected in our
RT-PCR analysis, we decided to include also the truncated protein in our functional assays. The
genetic constructs for eukaryotic expression of p53ΔY126, p53-aa125 and the wild type p53 as
the N-terminal fusions to the enhanced green fluorescent protein were generated using the
pEGFP-N1 vector, and first, were transiently transfected into immortalised human fibroblasts.
Both the wild type p53 and p53ΔY126 were predominantly localised in the nuclei (Fig 4A and
4C, respectively) in 24 hours after transfection, consistent with previous observations in which
the p53wt-EGFP fusion protein was detected in the nuclei [29]; whereas the p53-aa125 protein
was distributed through the entire cell (Fig 4E); a similar staining was produced with a parental
vector alone.
The other experiments were carried out using the cell lines with p53 null genotype to avoid
competition between endogenously and exogenously expressed p53 proteins. When the plas-
mids were transfected into K562 cells, all the p53-EGFP fusion proteins were expressed as con-
firmed by Western blotting (S2 File, Supporting Information). After transfection of K562 cells,
p53ΔY126 induced the p21/Waf1 expression as well as the wild type p53, whereas p53-aa125
failed to do it as well as the carrier vector (Fig 5A). These results indicate that the p53ΔY126
protein is able to regulate one of the essential p53 target genes. The truncated p53-aa125 pro-
tein does not contain the DNA binding domain, and therefore, its inability to activate down-
stream genes was not surprising.
One of the most important p53 functions is its ability to induce apoptotic cell death. To
assess this activity of the p53ΔY126 protein, we first performed a cell viability assay using
GL-V cells [22]. Fig 5B shows that the cells transfected with the plasmids driving the expres-
sion of either the wild type or the p53ΔY126 protein eventually died when were cultivated in
the presence of antibiotic G418, whereas the cells expressing the p53-aa125 protein survived.
Consistent with this result, we were unable to select stably transfected cell lines expressing the
wild-type p53-EGFP fusion or p53ΔY126-EGFP following successful transient transfections of
the cells carrying the wild-type p53 gene (see Fig 3 as an example) as all the clones initially
emitting fluorescence were dying upon antibiotic selection. Finally, using flow cytometry we
measured the induction of apoptosis in K562 cells at 48 h after transfection [23]. If p53-aa125
was inactive, the expression of both the wild-type and p53ΔY126 proteins induced apoptosis
albeit the number of apoptotic cells transfected with the mutant was approximately 2-fold
lower compared with the wild type (Fig 5C). Overall, our results demonstrate that the
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p53ΔY126 protein is nearly as active as the wild type protein as far as the p21/Waf1 induction
and the p53-induced apoptosis are concerned, whereas the 125aa truncated protein is silent in
this respect.
Discussion
P53 is commonly recognized as the most important tumour suppressor protein due to its role
in inducing cell cycle arrest or programmed cell death; thus preventing uncontrolled cell divi-
sions or propagation of the cells with damaged genomes. Most of its functions were discovered
from studies using cells carrying mutations in the p53 gene. Historically, p53 mutations
Fig 4. p53-EGFP expression in NB1-T cells 24 hours after transfection with plasmids driving the
expression of the wild type p53 (A, B), p53ΔY126 (C, D), p53-aa125 (E, F). Panels A, C, E show green
fluorescence originated from the EGFP; panels B, D, F–blue fluorescence from counterstaining with DAPI.
https://doi.org/10.1371/journal.pone.0185126.g004
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leading to the loss of the wild-type function were thought to provide the main contribution of
p53 in developing cancer. However, the emerging role for p53 mutants in tumour formation
and progression via a gain-of-function mechanism has already generated increased interest in
studying the impact of the specific p53 mutants at molecular, cellular and physiological levels.
This study has focused on a C to G nucleotide substitution at position 378 of the p53 pro-
tein, which we identified in two clinical samples derived from brain and colorectal cancer. We
screened the p53 and cell lines databases and found the cell lines carrying 378C>G mutation;
two of them–EJ and ECV-304 were available to us. These cell lines are not our preferred
choice, but it was inevitable one as the only way to study this mutation at the cellular level. EJ
and ECV-304 were widely used cell lines since early 1980s and 1990s, respectively [30–32] but
were included into the list of suspicious cell lines that are likely to be cross-contaminated or
misidentified many years ago. Indeed, the early short tandem repeat (STR) profiling revealed
that ECV-304, EJ and T24 are characterised by the identical STR pattern [17]. The most recent
detailed annotations of the cell line inventory suggest these three cell lines are likely to be the
same and now consider the ECV-304 and the EJ cell lines as contaminants, and the human
T24 bladder carcinoma cell line as a parental or authentic one [19,33]. Despite of this, all the
three cell lines are still currently used in many laboratories around the world. In addition,
there are contradictory data on the p53 mutational status in EJ cells varying from no mutations
[24] to point mutations at the different nucleotides [25,26] as well as some controversy about
positive immunological staining of p53 protein in the cells and negative detection on Western
blots.
Sequencing analysis revealed that our ECV-304 and EJ cells contain only one single
nucleotide mutation - 378C>G. This is present on both alleles of the p53 gene and creates a
stop codon (TAG) instead of tyrosine at amino acid position 126 (Y126 –TAC). Unexpect-
edly, a band corresponding to the full-length p53 protein size was detected on the immuno-
blots whereas the truncated 125-aa protein was not. This could only be explained at the
post-transcriptional level. There is a natural phenomenon, a stop codon readthrough, that
occurs at authentic termination codons, albeit at a very low frequency (10−4) [34]. The
premature termination codons (PTC) are readthrough by the ribosomes much more often
with a help of the close-loop mRNA structure formed via interactions between the proteins
bound to the 5’ end and to the poly(A) tail at the 3’ end of mRNA; however, frequencies of
Fig 5. Functional properties of the p53ΔY126 and p53-aa125 proteins compared to the wild type protein. (A) Induction of the p21/Waf1 expression by
transient transfection of K562 cells with plasmids expressing different variants of p53 proteins. Mock corresponds to transfection with the vector pEGFP-N1.
Cells were collected 24 hours after transfection, and the total cell extracts were analysed by Western blotting with the p21/Waf1 antibody and the GAPDH
antibody used as an endogenous control. (B) Cell viability assay for the GL-V cells transfected with the corresponding plasmids. (C) Flow cytometry analysis
of the p53-induced apoptosis in the K562 cells transfected with the corresponding plasmids. The paired t-Test was used for statistical analysis of the mock
transfected cells and the cells transfected with p53-aa125 or p53ΔY126 or p53wt using data from at least three independent experiments. Asterisk (*)
represents the statistical significant difference with P-value <0.05.
https://doi.org/10.1371/journal.pone.0185126.g005
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termination suppression at PTCs are still below 1% [35]. Thus, a stop codon readthrough
can’t solely explain the presence of full-length p53 protein in EJ and ECV-304 cells.
The other possibility is an alternative pre-mRNA splicing. Indeed, we provide here the evi-
dences that the nonsense mutation at the beginning of exon 5 generates the alternative 3’ss
which is used in more than 50% splicing events. This allows the splicing machinery to skip a
stop codon and synthesise the p53 protein with a single amino acid deletion (p53ΔY126). The
378C>G mutation creates the NAGNAG motif that contains two 30 ss in tandem. Hiller et al.,
2004 [36] estimated that the NAGNAG motif is present in 30% of human genes and suggested
that it may play a functional role in about 5% of the genes. Using an EST-derived alternative
splicing database, Dou at al., 2006 [37] provided evidences that the NAGNAG motif is indeed
subjected to alternative splicing in about 50% cases. Nevertheless, analysis of different nucleo-
tides at position N of the NAGNAG consensus sequence [38] does not support preferential use
of the downstream 3’ ss in the context of the mutant 378C>G. At the same time, our results
cast some support in favour of a general mechanism that triggers the alternative splicing events
to avoid a PTC [39].
Interestingly, Liu and Bodmer, 2006 [40] reported the presence of the 378C>G mutation in
the colorectal cancer cell line CC20 as well as the detection of p53 protein by antibody DO-1
(the same antibody used in this study); however, it is not clear whether the truncated protein
of 125 aa or a full-length protein was detected there. It is also possible that the tongue squa-
mous cell carcinoma BICR 56 cell line also carries the 378C>G mutation [41]. The authors
reported the deletion of 21 nucleotides in the p53 cDNA prepared from BICR 56 cells that cor-
responds to an in-frame deletion of seven amino acid residues 126–132, and could be triggered
by stop codon mutation at the genomic level. If proven, it would be an interesting example of
how one nonsense mutation can activate two, probably competing, alternative splice sites, but
both would save an open reading frame.
RT-PCR analysis revealed that at least 23% of all mRNAs encoded by the p53 gene in EJ
and ECV-304 cells contain the stop codon, despite meeting the requirements for degradation
via NMD. Mammalian NMD is triggered when a ribosome stalls at the PTC, which is located
over 55 nt upstream of an exon-exon junction, and forms a network of protein-protein inter-
actions with the exon-junction complex which is deposited during splicing on mRNA 20–25
nt upstream of exon-exon junction [42]. Even if the importance of NMD is underscored by the
fact that about 30% of mutations linked to human diseases generate PTCs [43], we are still far
from elucidation of the NMD pathway as there are experimental data showing that not every
PTC triggers NMD and that an abundance of some authentic mRNAs is also regulated via
NMD.
If the p53 mRNAs containing the stop codon escape NMD in EJ and ECV cells, the trun-
cated protein of 125 amino acids (p53-aa125) can be synthesised; however, we were unable to
detect this protein using the p53 antibody recognising the N-terminal epitope. This indicates
that either the truncated protein is rapidly degraded or our RT-PCR analysis partially detected
the RNAs which have not been released from the nucleus yet. Nevertheless, if the truncated
protein is produced in the cells, it is very unlikely that it exhibits dominant-negative properties
as we didn’t find any activity of p53-aa125 in our assays. In contrast, the p53ΔY126 protein,
transiently produced in the cells lacking the p53 gene, induces the expression of one of the
important target genes in the p53 pathway—p21/Waf1. The p53ΔY126 protein also causes cell
death with efficiency comparable to the wild-type protein, despite the absent tyrosine is a
highly conserved residue (S3 File, Supporting Information). Also, consistent with numerous
data that the expression of p53 induces apoptosis [44–46], we have failed to generate a stable
cell line following the successful transient expression of either the wild type p53 or p53ΔY126
protein fused to EGFP.
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Our work highlights the lack of extensive experimental data on the p53 mutations that can
potentially trigger alternative pre-mRNA splicing responsible for the production of p53 pro-
teins which may exhibit new properties affecting the cellular functions. Blocking the produc-
tion of such a protein may provide new therapeutic targets; amongst them could be the
components of splicing machinery [47].
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